Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Share:
More In Business
Bristol Myers to Buy Cancer Drug Developer Rayzebio
Bristol Myers to Buy Cancer Drug Developer Rayzebio
Mastercard Poll: Spending Up 3.1 Percent This Holiday Shopping Season
Mastercard Poll: Spending Up 3.1 Percent This Holiday Shopping Season
Toyota-Owned Daihatsu to Halt All Japanese Production
Toyota-Owned Daihatsu to Halt All Japanese Production
Softbank to Receive $7.59B Worth of T-Mobile Shares
Softbank to Receive $7.59B Worth of T-Mobile Shares
Workers' Strike Shuts down Eiffel Tower
Workers' Strike Shuts down Eiffel Tower
Amazon to Introduce Ads on Prime Video on Jan. 29
Amazon announced it would be bringing advertisements to its streaming service, Prime Video, at the end of January.
The New York Times Sues Microsoft and OpenAI
The New York Times has filed a lawsuit against Microsoft and Open AI, accusing both of infringing copyright and abusing the intellectual property of the newspaper.
Study: Why People Work During the Holidays
A new study is revealing how many people worked over the Christmas holiday.
Bristol Myers Squibb to Buy Cancer Drug Developer RayzeBio
Bristol Myers Squibb says it will buy drug developer RayzeBio for about $4.1 billion.
